# Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination

> **NCT04247074** · PHASE3 · COMPLETED · sponsor: **Galderma R&D** · enrollment: 413 (actual)

## Conditions studied

- Glabellar Frown Lines (GL)
- Lateral Canthal Lines (LCL)

## Interventions

- **BIOLOGICAL:** botulinum toxin neuromodulator
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04247074
- **Lead sponsor:** Galderma R&D
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-10
- **Primary completion:** 2020-10-02
- **Final completion:** 2021-02-26
- **Target enrollment:** 413 (ACTUAL)
- **Last updated:** 2023-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04247074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04247074, "Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04247074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*